Final Progression-Free Survival Analyses for Lanreotide Autogel/Depot 120 mg in Metastatic Enteropancreatic Neuroendocrine Tumors: The CLARINET Extension Study

被引：0

作者：

Wolin, Edward M. ^{[1
]}

Pavel, Marianne E. ^{[2
]}

Cwikla, Jaroslaw B. ^{[3
]}

Phan, Alexandria T. ^{[4
]}

Raderer, Markus ^{[5
]}

Sedlackova, Eva ^{[6
,7
]}

Cadiot, Guillaume ^{[8
]}

Capdevila, Jaume ^{[9
]}

Wall, Lucy ^{[10
]}

Rindi, Guido ^{[11
]}

Lombard-Bohas, Catherine ^{[12
]}

Liyanage, Nilani ^{[13
]}

Thanh, Xuan-Mai Truong ^{[14
]}

Ruszniewski, Philippe B. ^{[15
]}

Caplin, Martyn E. ^{[16
]}

Investigators, Clarinet ^{[17
]}

机构：

[1] Montefiore Einstein Ctr Canc Care, New York, NY USA

[2] Univ Klinikum Erlangen, Erlangen, Germany

[3] Univ Warmia & Mazury, Olsztyn, Poland

[4] Canc Treatment Ctr Amer, Atlanta, GA USA

[5] Univ Hosp, Vienna, Austria

[6] First Fac Med, Prague, Czech Republic

[7] Gen Teaching Hosp, Prague, Czech Republic

[8] Robert Debre Hosp, Reims, France

[9] Vall dHebron Univ Hosp, Barcelona, Spain

[10] Western Gen Hosp, Edinburgh, Midlothian, Scotland

[11] Univ Cattolica Sacro Cuore, Rome, Italy

[12] Hosp Civils Lyon, Edouard Herriot Hosp, Lyon, France

[13] Ipsen, Les Ulis, France

[14] Ipsen, Boulogne, France

[15] Beaujon Hosp, Clichy, France

[16] Royal Free Hosp, London, England

[17] CLARINET Study Investigators, London, England

来源：

PANCREAS | 2018年 / 47卷 / 03期

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

页码：358 / 359

页数：2

共 50 条

[21] Novel Tumor Growth Rate Analysis in the Randomized CLARINET Study Establishes the Efficacy of Lanreotide Depot/Autogel 120 mg with Prolonged Administration in Indolent Neuroendocrine Tumors
Dromain, Clarisse
Loaiza-Bonilla, Arturo
Mirakhur, Beloo
Beveridge, Thomas J. R.
Fojo, Antonio Tito
ONCOLOGIST, 2021, 26 (04): : E632 - E638
[22] Lanreotide Autogel (LAN) 120 mg Every 14 Days in Progressive Pancreatic Neuroendocrine Tumors (panNETs): CLARINET FORTE Study
Pavel, M.
Cwikla, J.
Lombard-Bohas, C.
Borbath, I.
Shah, T.
Pape, U. -F.
Thanh, X. -M. Truong
Houchard, A.
Ruszniewski, P.
PANCREAS, 2021, 50 (03) : 448 - 448
[23] Tumor Response in the CLARINET Study of Lanreotide Depot/Autogel vs Placebo in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (03) : 11 - 12
[24] Effects of lanreotide autogel/depot (LAN) in pancreatic neuroendocrine tumors (pNETs): A subgroup analysis from the CLARINET study
Phan, Alexandria T.
Caplin, Martyn E.
Pavel, Marianne E.
Cwikla, Jaroslaw B.
Raderer, Markus
Sedlackova, Eva
Cadiot, Guillaume
Wolin, Edward M.
Capdevila, Jaume
Wall, Lucy
Rindi, Guido
Langley, Alison
Gomez-Panzani, Edda
Ruszniewski, Philippe B.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
[25] Lanreotide depot/autogel (LAN) in pancreatic neuroendocrine tumors (pNETs): A subgroup analysis from the CLARINET study.
Phan, Alexandria T.
Caplin, Martyn E.
Pavel, Marianne E.
Cwikla, Jaroslaw B.
Raderer, Markus
Sedlackova, Eva
Cadiot, Guillaume
Wolin, Edward M.
Capdevila, Jaume
Wall, Lucy
Rindi, Guido
Langley, Alison
Gomez-Panzani, Edda
Ruszniewski, Philippe B.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[26] Relationship between lanreotide autogel, chromogranin A and progression-free survival in patients with gastroenteropancreatic neuroendocrine tumours
Buil-Bruna, N.
Dehez, M.
Manon, A.
Xuan, Q. N. Thi
Troconiz, I.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S448 - S448
[27] Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors
Pavel, Marianne E.
Phan, Alexandria T.
Wolin, Edward M.
Mirakhur, Beloo
Liyanage, Nilani
Lowenthal, Susan Pitman
Fisher, George A., Jr.
Vinik, Aaron I.
ONCOLOGIST, 2019, 24 (04): : 463 - 474
[28] Establishing the Quantitative Relationship Between Lanreotide Autogel®, Chromogranin A, and Progression-Free Survival in Patients with Nonfunctioning Gastroenteropancreatic Neuroendocrine Tumors
Núria Buil-Bruna
Marion Dehez
Amandine Manon
Thi Xuan Quyen Nguyen
Iñaki F. Trocóniz
The AAPS Journal, 2016, 18 : 703 - 712
[29] Antitumor Treatment with Lanreotide Autogel 120 mg (LAN) for Enteropancreatic (EP-) NET: Update from the CLARINET Open-Label Extension (OLE) Study
Caplin, M.
Pavel, M.
Cwikla, J. B.
Phan, A. T.
Raderer, M.
Sedlackova, E.
Cadiot, G.
Wolin, E. M.
Capdevila, J.
Wall, L.
Rindi, G.
Langley, A.
Gomez-Panzani, E.
Ruszniewski, P. B.
NEUROENDOCRINOLOGY, 2015, 102 (1-2) : 123 - 123
[30] Progression-Free Survival (PFS) and Tumor Growth with Lanreotide Autogel (LAN) in Patients (Pts) with Enteropancreatic NETs: Results from CLARINET, a Randomized, Double-Blind, Placebo (Pbo)-Controlled Study
Caplin, M.
Ruszniewski, P.
Pavel, M.
Cwikla, J.
Phan, A.
Raderer, M.
Sedlackova, E.
Cadiot, G.
Wall, L.
Rindi, G.
Langley, A.
Blumberg, J.
NEUROENDOCRINOLOGY, 2014, 99 (3-4) : 270 - 270

← 1 2 3 4 5 →